Answers are grounded in this paper and cite their sources.
Mutations in TP53 occur across many cancers, yet the intracellular location of the p53 protein makes it difficult to target with traditional antibody-based therapies. However, mutant peptides, including those derived from p53, can be displayed by human leukocyte antigen (HLA) molecules on the cancer cell surface as peptide-HLA (pHLA) complexes, offering a route to selectively target intracellular mutant proteins. While potentially attractive, these pHLA complexes are often scarce on tumor cells and differ from their normal counterparts by only one amino acid, making selective recognition technically challenging.
No takes yet. Share an insight, caveat, or question.
Jacqueline Douglass (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: